Financière de Tubize SAの機関の所有権
Financière de Tubize SAの機関の所有権は何ですか。
Financière de Tubize SAの機関の所有権は0.96%です。
機関の所有権の定義は何ですか。
機関所有権は、ミューチュアル・ファンドまたは年金基金、保険会社、投資会社、その他の資金を管理する他の団体が所有する会社の株式数です。
Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.
Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.
EURONEXTのセクタHealth Careにおける機関の所有権の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の機関の所有権
- China Unicom (Hong Kong) Ltdの機関の所有権は0.95%です。
- UBS ETF (CH) - SPI Midの機関の所有権は0.95%です。
- Borosil Renewablesの機関の所有権は0.96%です。
- Batero Goldの機関の所有権は0.96%です。
- Qurate Retail Incの機関の所有権は0.96%です。
- Jiangnanの機関の所有権は0.96%です。
- Financière de Tubize SAの機関の所有権は0.96%です。
- Teuton Resourcesの機関の所有権は0.96%です。
- Homes & Holiday AGの機関の所有権は0.96%です。
- Happy Creek Mineralsの機関の所有権は0.96%です。
- Tajiri Resourcesの機関の所有権は0.96%です。
- Atari SAの機関の所有権は0.96%です。
- YASKAWA Electricの機関の所有権は0.97%です。